Chronic Rhinosinusitis With Nasal Polyps research hub
11 indexed studies · 2 currently recruiting
- enrolling by invitationPHASE2
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
This study looks at how safe and effective a medicine called lunsekimig is over a long time for adults with long-lasting nose and sinus problems, especially those with nasal polyps, who have already used lunsekimig in a previous study.
United States · Argentina · Belgium - enrolling by invitationPHASE3
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
This study looks at the long-term safety and effects of a medicine called itepekimab for adults with a condition called chronic rhinosinusitis with nasal polyps, which causes stuffy nose and other symptoms. This is an extension study for people who were already in an earlier trial.
United States · Australia · Canada - active not recruitingPHASE3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
This study looks at a new medicine called Itepekimab for people with long-term sinus problems and nasal polyps. It checks if the medicine works, is safe, and if people can tolerate it well, compared to a dummy medicine or standard nasal spray.
United States · Argentina · Austria - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.
This study is comparing a new version of a common medicine, Xolair, with the original. It's looking at how the new medicine works in the body, its safety, and if it causes an immune reaction. This is for healthy people, not those with existing conditions.
Spain - authorisedTherapeutic use (Phase IV)
Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting
This study compares two medicines, Dupixent and Tezspire, for treating long-term nasal polyps. Researchers want to see which medicine works better in real-world use to improve symptoms like stuffy nose and sense of smell over 12 months.
Austria - authorisedTherapeutic confirmatory (Phase III)
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
This study is looking at the long-term safety of a new medicine, itepekimab, for adults with nose polyps and ongoing sinus problems. It's for people who were in earlier trials and helps us understand if the treatment is safe over time.
Germany · Netherlands · Portugal - active not recruitingPHASE3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
This study is testing a new drug, itepekimab, for people with long-term sinus problems and nasal polyps that haven't been controlled by usual treatments. We want to see if it helps reduce symptoms and if it's safe to use.
United States · Argentina · Australia - ongoing, recruitingTherapeutic use (Phase IV)
A phase IV, randomized double blinded placebo-controlled study on the barrier restoring capacity of Dupilumab in type 2 airway disease: CRSwNP
Belgium - ongoing, recruitingTherapeutic use (Phase IV)
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)
Estonia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Germany · Czechia · Spain - ongoing, recruitingTherapeutic use (Phase IV)
Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study
Austria